-
Mashup Score: 0
PURPOSE: Cancer trial participants do not reflect the racial and ethnic diversity in the population of people with cancer in the United States. As a result of multiple system-, patient-, and provider-level factors, including implicit bias, cancer clinical trials are not consistently offered to all potentially eligible patients. MATERIALS AND METHODS: ASCO and ACCC evaluated the utility (pre- and…
Source: JCO Oncology PracticeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 28
> JCO Oncology Practice > …
Source: JCO Oncology PracticeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
RT @jamecancerdoc: Management of Metastatic Clear Cell Renal Cell Carcinoma: @ASCO Guideline Q&A https://t.co/uG8CFKnTAh @OncoAlert @JCOOP_…
-
-
Mashup Score: 0
PURPOSE: Prompt recognition of acute chimeric antigen receptor T (CAR T)-cell–mediated toxicities is crucial because adequate and timely management can prevent or reverse potential life-threatening complications. In the outpatient setting, patients and informal caregivers have to recognize and report signs and symptoms marking these acute toxicities. This study provides a core set of patient- and…
Source: JCO Oncology PracticeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
This study (systematic review ➡️ modified delphi x2 ➡️ pt/#caregiver evaluation) developed a core set of patient/caregiver-reported signs & symptoms flagging acute CAR-T toxicity to enhance safe outpatient treatment 👉 https://t.co/M9k8PVuf5P #ePROmonitoring @Kersten_MJ https://t.co/Cxonpf1zTr
-
-
Mashup Score: 0Substance Use Among Young Adult Survivors of Childhood Cancer With Cognitive Impairment: An Analysis of the Project Forward Cohort - 1 year(s) ago
PURPOSE: Young adult childhood cancer survivors (YACCSs) are often impacted by cancer-related cognitive impairment (CRCI) and psychological distress. Using the Project Forward Cohort, we evaluated the relationship between CRCI and substance use behaviors. METHODS: YACCSs were surveyed between 2015 and 2018 (N = 1,106, female = 50.8%, Hispanic = 51.5%, median age = 25.5 years). Associations…
Source: JCO Oncology PracticeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
13% of #AYAc survivors deal w/ cancer-related cognitive impairment; those that did were twice as likely (OR 2.26) to vape in the prior 30-days. Mediators include: depression & ≥2 cancer-related late effects. ➡️ https://t.co/CkSjoRrapz #AYACSM @alexchan928; @dquin_ng https://t.co/p9I8cnsPbi
-
-
Mashup Score: 4
In the spring of 2022, a man with a persistent cough sought care at an emergency department and was ultimately diagnosed with metastatic testicular cancer. He is presumably undergoing treatment though we do not know if that is true. We say presumably because we do not personally know this patient. We only know of him because we saw his chest X-ray on social media in a post that challenged the…
Source: JCO Oncology PracticeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#WithConsent shows the audience the content creator is sensitive and respectful of the person behind the image. A patient perspective on medical images posted to #SocialMedia #SoMe without consent: https://t.co/ekBEYMOfkT @Jso7151 @chemobrainfog #OncTwitter #MedTwitter
-
-
Mashup Score: 1OPTIMAL Breast Cancer Care: Effect of an Outpatient Pharmacy Team to Improve Management and Adherence to Oral Cancer Treatment - 1 year(s) ago
PURPOSE: Since the approval of cyclin‐dependent kinase 4/6 inhibitors in 2015, this oral cancer (OC) therapy has been combined with oral endocrine therapy as first-line treatment in metastatic hormone receptor–positive breast cancer, adding unique toxicity and complexity to the successful administration of this oral medication. Implementation of OC is challenging because of delays in treatment…
Source: JCO Oncology PracticeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#QualityinAction: A #pharmacist-driven intervention can decrease treatment delays in patients w/ #mBC on oral cancer 💊 from 8 to 2 days. Specialty pharmacists have a role in identifying and mitigating barriers ➡️ https://t.co/fo8IzF22mO #oncpharm @JPatel_PharmD @NaomiKoMD https://t.co/YlPifatxth
-
-
Mashup Score: 0Sociodemographic Differences in Patient-Reported Pain and Pain Management of Patients With Head and Neck Cancer in a Community Oncology Setting - 1 year(s) ago
PURPOSE: While pain is prevalent among survivors of head and neck cancer (HNC), there is a lack of data on pain management in the community oncology setting. We described sociodemographic correlates and disparities associated with patient-reported pain among patients with HNC. METHODS: We used the 2017-2021 nationwide community oncology data set from Navigating Cancer, which included electronic…
Source: JCO Oncology PracticeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
While there was no differences in pain reported by White vs non-White patients with #HeadandNeckCancer, White pts were more than twice as likely to receive new pain medications when compared to non-White pts 👉 https://t.co/y1OHgCqNae #hncsm @juliacanick @Duke_Oto https://t.co/OwOWeVKssW
-
-
Mashup Score: 0Scoping Review to Inform the Future Development of a Measure for Team-Based Care in Oncology - 1 year(s) ago
PURPOSE: Team-based care is the delivery of health services to an individual by at least two health care providers working collaboratively to achieve optimal care. Participants on the National Cancer Institute and the ASCO Teams in the Cancer Care Delivery Project have defined 13 key principles to serve as the foundation for a successful team; however, it is unclear whether there exist measures…
Source: JCO Oncology PracticeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#TeamBasedCare is the delivery of health services to an individual by ≥2 providers working collaboratively to achieve optimal care. This scoping review discusses what measures can assess key principles of team function in oncology. 👉 https://t.co/q38aUIXFNp @rada_zunich https://t.co/ZlW6Bpd3fg
-
-
Mashup Score: 1A Learning Health System Approach to Cancer Survivorship Care Among LGBTQ+ Communities - 1 year(s) ago
PURPOSE: Lesbian, gay, bisexual, transgender, and queer (LGBTQ+) individuals who receive primary care services at community health centers are often referred to external specialty care centers after cancer diagnosis, upon which primary care services are disrupted and may be discontinued because of gaps in communication between primary and oncologic care providers. This qualitative study evaluated…
Source: JCO Oncology PracticeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
"The person that they had referred me to had never seen a trans patient": This study qualitatively investigates care coordination & patient-clinician communication specifically for #LGBTQ+ pts with cancer & LGBTQ+ #cancersurvivors. ➡️ https://t.co/lDvlxLf8OI @DrMelissaSimon https://t.co/5WkiJl0B8x
-
-
Mashup Score: 0Comparison of Oncologist and Model Estimates of Risk for Hospitalization During Systemic Therapy for Advanced Cancer - 1 year(s) ago
PURPOSE: A validated risk model with inputs of pretreatment sodium and albumin can identify patients at risk for hospitalization during cancer treatment. We evaluated how the model compares with risk estimates from treating oncologists. METHODS: We evaluated the 30-day risk of hospitalization or death in patients starting palliative-intent systemic therapy for solid tumor malignancy. For each…
Source: JCO Oncology PracticeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
A 2-variable risk model (using pre-tx sodium & albumin) performed as well as the treating oncologist in identifying pts at risk for hospitalization w/in 30d of palliative intent chemo. A hybrid model may improve prediction 🎯 even more. 👉 https://t.co/IrfB3bNbnw @gabe_a_brooks https://t.co/bCE5zKgiEW
-
Results in #JCOOP from @ASCO & @ACCCBuz Just ASK™ Implicit Bias Training pilot showed an increase in knowledge of the key concepts of #implicitbias, and of strategies to address implicit bias & diversity concerns in cancer #clinicaltrials. https://t.co/d2BxN0V6A8 #healthequity